Page 96 - 《中国药房》2023年19期

and Clinical Microbiology （SEIMC） on the diagnosis and tional consensus guidelines for the optimal use of the poly‐
antimicrobial treatment of infections due to carbapenem- myxins：endorsed by the American College of Clinical
resistant Gram-negative bacteria[J]. Enferm Infecc Micro‐ Pharmacy （ACCP），European Society of Clinical Micro‐
biol Clin，2023，41（6）：360-370. biology and Infectious Diseases （ESCMID），Infectious
[ 8 ] TAMMA P D，AITKEN S L，BONOMO R A，et al. Infec‐ Diseases Society of America （IDSA），International
tious Diseases Society of America 2022 guidance on the Society for Anti-infective Pharmacology （ISAP），Society
treatment of extended-spectrum β-lactamase producing en‐ of Critical Care Medicine （SCCM），and Society of Infec‐
terobacterales （ESBL-E），carbapenem-resistant enterobac‐ tious Diseases Pharmacists （SIDP）[J]. Pharmacotherapy，
terales （CRE），and Pseudomonas aeruginosa with diffi- 2019，39（1）：10-39.
cult-to-treat resistance （DTR-P. aeruginosa）[J]. Clin [15] AHMED M U，VELKOV T，LIN Y W，et al. Potential to-
Infect Dis，2022，75（2）：187-212. xicity of polymyxins in human lung epithelial cells[J].
[ 9 ] PAUL M，CARRARA E，RETAMAR P，et al. European Antimicrob Agents Chemother，2017，61（6）：e02690-
Society of Clinical Microbiology and Infectious Diseases e02616.
（ESCMID） guidelines for the treatment of infections [16] VARDAKAS K Z，MAVROUDIS A D，GEORGIOU M，
caused by multidrug-resistant Gram-negative bacilli （en‐ et al. Intravenous plus inhaled versus intravenous colistin
dorsed by European Society of Intensive Care Medicine） monotherapy for lower respiratory tract infections：a sys‐
[J]. Clin Microbiol Infect，2022，28（4）：521-547. tematic review and meta-analysis[J]. J Infect，2018，76
[10] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊 （4）：321-327.
断和治疗指南：2016 年版[J]. 中华结核和呼吸杂志， [17] ZHANG X Y，CUI X X，JIANG M K，et al. Nebulized co‐
2016，39（4）：253-279. listin as the adjunctive treatment for ventilator-associated
Chinese Thoracic Society. Guidelines for diagnosis and pneumonia：a systematic review and meta-analysis[J]. J
treatment of adult community-acquired pneumonia in Crit Care，2023，77：154315.
China：2016 edition[J]. Chin J Tuberc Respir Dis，2016，39 [18] CUI H M，LIN X，LIU Y Y，et al. Comparison of different
（4）：253-279. colistin regimens for the treatment of pneumonia caused
[11] 《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临 by multidrug-resistant microorganisms：a systematic re‐
床试验技术指导原则附件：抗菌药物立题原则建议[J]. view and meta-analysis[J]. Eur Rev Med Pharmacol Sci，
中国临床药理学杂志，2014，30（9）：857-858. 2021，25（16）：5275-5292.
Writing Group of Guidance for Clinical Trials of Antibac‐ [19] MATTOS K P H，CINTRA M L，GOUVÊA I R，et al.
terial Drugs. Guidance for clinical trials of anti-bacterial Skin hyperpigmentation following intravenous polymyxin
drugs appendix：antimicrobial reference principle sugges‐ B treatment associated with melanocyte activation and in‐
tion[J]. Chin J Clin Pharmacol，2014，30（9）：857-858. flammatory process[J]. J Clin Pharm Ther，2017，42（5）：
[12] U.S. Department of Health and Human Services. Common 573-578.
terminology criteria for adverse events （CTCAE） v5.0 [20] 胡付品，郭燕，吴湜，等 . CHINET 中国细菌耐药监测结
[EB/OL]. [2023-07-24]. https：//ctep.cancer.gov/proto‐ 果：2022 年 1－12 月[EB/OL]. [2023-07-24]. http：//www.
colDevelopment/electronic_applications/ctc. htm#ctc_ chinets.com/Document/Index?pageIndex=0.
archive. HU F P，GUO Y，WU S，et al. CHINET surveillance re‐
[13] 杜光，赵杰，卜书红，等. 雾化吸入疗法合理用药专家共 sults of bacterial resistance in China：January to December
识：2019年版[J]. 医药导报，2019，38（2）：135-146. 2022[EB/OL]. [2023-07-24]. http：//www. chinets. com/
DU G，ZHAO J，BU S H，et al. Expert consensus on ratio‐ Document/Index?pageIndex=0.
nal drug use in aerosol inhalation therapy：2019 edition[J]. （收稿日期：2023-05-06 修回日期：2023-09-12）
Her Med，2019，38（2）：135-146. （编辑：胡晓霖）
[14] TSUJI B T，POGUE J M，ZAVASCKI A P，et al. Interna‐

· 2390 · China Pharmacy 2023 Vol. 34 No. 19 中国药房 2023年第34卷第19期